RPRX

32.20

0.53% 0.17

Vorhandelsmarkt: 31.60 -0.60 -1.86%

Royalty Pharma Plc (RPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$32.03

Offen:

$31.99

24-Stunden-Volumen:

3.44M

Relative Volume:

0.77

Marktkapitalisierung:

$13.95B

Einnahmen:

$2.27B

Nettoeinkommen (Verlust:

$1.15B

KGV:

12.63

EPS:

2.55

Netto-Cashflow:

$2.80B

1W Leistung:

-1.23%

1M Leistung:

-4.62%

6M Leistung:

+19.48%

1J Leistung:

+14.55%

1-Tages-Spanne:

$31.84

$32.30

1-Wochen-Bereich:

$31.58

$32.73

52-Wochen-Spanne:

$24.05

$34.20

Royalty Pharma Plc Stock (RPRX) Company Profile

Firmenname

Royalty Pharma Plc

Sektor

Healthcare (1155)

Branche

Biotechnology (677)

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

RPRX's Discussions on Twitter

Vergleichen Sie RPRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPRX Royalty Pharma Plc	32.20	13.95B	2.27B	1.15B	2.80B	2.55
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Fortgesetzt	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Fortgesetzt	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Alle ansehen

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

05:02 AM

Royalty Pharma plc (NASDAQ:RPRX) Declares $0.22 Quarterly Dividend - MarketBeat

05:02 AM

Apr 27, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by GMT Capital Corp - MarketBeat

Apr 27, 2025

25,124 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Walleye Capital LLC - MarketBeat

Apr 27, 2025

Brokerages Set Royalty Pharma plc (NASDAQ:RPRX) Price Target at $42.50 - MarketBeat

Apr 27, 2025

Apr 26, 2025

Cerity Partners LLC Sells 15,537 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 26, 2025

Uniplan Investment Counsel Inc. Acquires New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 26, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Dark Forest Capital Management LP - MarketBeat

Apr 26, 2025

Apr 25, 2025

Canada Pension Plan Investment Board Buys 39,070 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Guggenheim Capital LLC Sells 82,768 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat

Apr 25, 2025

Barclays PLC Raises Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Raymond James Financial Inc. Buys Shares of 783,633 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Jump Financial LLC Makes New $2.09 Million Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Invesco Ltd. Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Apr 24, 2025

Bridgewater Associates LP Acquires New Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 24, 2025